Profluent

Research on the record

• 2025-07-30Profluent's language-model-designed gene editor OpenCRISPR-1 edits human cells, in NatureLevel 4 · Tested in the physical world

Graded by how far the evidence went, not how good the result is. See the methodology.

Also on the timeline

• 2026-09-30Profluent and BioMarin agree to design enzyme replacement therapies with Profluent's protein models, on terms neither namesPartnerships
• 2026-04-28Lilly will license recombinases Profluent is to design with AI, enzymes for writing long DNA into the genome: upfront undisclosed, up to $2.25B in milestonesPartnerships

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2025-11-19Round (unnamed) · $106MconfirmedLed by Altimeter Capital, Bezos Expeditions · With Spark Capital, Insight Partners, Air Street CapitalStated use: expand platform and markets beyond gene editors
• 2024-03-21Round (unnamed) · $35MconfirmedLed by Spark Capital · With Insight Partners, Air Street Capital, Jeff Dean (angel)Stated use: scale LLMs and datasets, wet lab, CRISPR gene editing
• 2023-01-26Seed · $9MconfirmedLed by Insight Partners · With Air Street Capital, AIX Ventures, Phoenix Venture PartnersStated use: build a wet lab in Berkeley and hire

Each round links to its line on the funding record, with its source.

Also in Protein design on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
• 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
• 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
• 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
• 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
• 2026-03-20Helixon (Earendil Labs)Round (unnamed) · $787MAI protein modelling plus high-throughput experiments to design antibodies, especially bispecifics, which it licenses to Sanofi and Genentech and develops in-house.

All 15 in this field →